Genomic Health, Inc. (GHDX) Set to Announce Quarterly Earnings on Monday
Genomic Health, Inc. (NASDAQ:GHDX) will be issuing its quarterly earnings data after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of $0.01 per share for the quarter.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The business had revenue of $85.50 million during the quarter, compared to analysts’ expectations of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.18) EPS. On average, analysts expect Genomic Health to post $-0.04 EPS for the current fiscal year and $0.36 EPS for the next fiscal year.
Genomic Health, Inc. (NASDAQ:GHDX) opened at 33.72 on Monday. Genomic Health, Inc. has a 12-month low of $26.37 and a 12-month high of $34.02. The stock’s market cap is $1.17 billion. The company has a 50 day moving average of $31.98 and a 200-day moving average of $31.72.
In other Genomic Health news, insider Kimberly J. Popovits sold 5,000 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $30.22, for a total value of $151,100.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider James J. Vaughn sold 8,000 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total value of $244,720.00. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock worth $1,022,620 in the last quarter. Insiders own 46.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/23/genomic-health-inc-ghdx-set-to-announce-quarterly-earnings-on-monday.html.
Several equities analysts recently weighed in on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $35.00 price target on shares of Genomic Health in a report on Wednesday, September 27th. BidaskClub downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. Jefferies Group LLC reaffirmed a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a research note on Friday. Finally, Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company’s stock. Genomic Health has a consensus rating of “Hold” and an average target price of $32.00.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.